NCT00068757View on ClinicalTrials.gov

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

November 30, 2007

Conditions

Breast Cancer

Interventions

BIOLOGICAL

trastuzumab

DRUG

lonafarnib

DRUG

paclitaxel

OTHER

pharmacological study

Trial Locations (3)

1000

Institut Jules Bordet, Brussels

75248

Institut Curie Hopital, Paris

1066 CX

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam

All Listed Sponsors

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00068757 - Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter